

Conversion of Community Marketing Authorisations to UK Marketing Authorisations – letter to industry

A second letter on conversion of Community Marketing Authorisations providing Product Licence numbers was sent on 2 January 2019 to Marketing Authorisation holders.

Published 21 January 2019

From:

[Medicines and Healthcare products Regulatory Agency](#)

Documents



[Letter to industry on Conversion of Community Marketing Authorisations to UK Marketing Authorisations](#)

PDF, 85.3KB, 2 pages

This file may not be suitable for users of assistive technology. [Request an accessible format.](#)

Details

The legislation that will come into force in a no-deal Brexit will, subject to being approved by Parliament, automatically convert Community Marketing Authorisations (CMAs) into UK Marketing Authorisations (MAs) on 29 March 2019 (so-called 'grandfathering').

To facilitate the grandfathering process, the MHRA has assigned a Product Licence (PL) number to CMAs based on the existing UK practice for national licences. These are listed in the annex to the letter. The letter also sets out the actions that companies are requested to take concerning that list of products.

We have allocated a PL number based on each presentation within the product range rather than a separate number for each pack size. This means that there will usually be fewer UK authorisation numbers issued compared with those issued by the European Medicines Agency.

If your company holds one or more CMA and has not received this second letter, please email capconversion@mhra.gov.uk so we can verify the appropriate contact details.

For more information see our guidance on [Converting Centrally Authorised Products \(CAPs\) to UK Marketing Authorisations \(MAs\), 'grandfathering' and managing lifecycle changes.](#)